Keyphrases
Allogeneic
100%
Stem Cell Donor
100%
Plerixafor
100%
Peripheral Blood Stem Cells
100%
Route of Administration
33%
Sibling Donor
33%
Interferon-α (IFN-α)
16%
Failure Rate
16%
Graft-versus-host Disease (GvHD)
16%
Gene Expression
16%
Cellular Composition
16%
Stem Cells
16%
Stem Cell Mobilization
16%
Hematopoietic Stem Cells
16%
Treatment-related Mortality
16%
Phenotypic Expression
16%
CD34+
16%
Efficacy Trial
16%
Stem Cell Genes
16%
Patients at Risk
16%
Apheresis
16%
Plasmacytoid Dendritic Cells
16%
Cytomegalovirus Viremia
16%
Subcutaneous Injection
16%
Stem Cell Markers
16%
Optimal Dose
16%
Recipient Outcomes
16%
Dendritic Cell Precursor
16%
Cell Yield
16%
Lower Stem
16%
Apheresis Collection
16%
Immunology and Microbiology
Plerixafor
100%
Peripheral Blood Stem Cell
100%
Stem Cell
50%
Apheresis
33%
interferon
16%
Graft-Versus-Host Disease
16%
Viremia
16%
Gene Expression
16%
Precursor
16%
Optimal Drug Dose
16%
CD34
16%
Cytomegalovirus
16%
Plasmacytoid Dendritic Cell
16%